Kadmon Holdings, Inc. (NASDAQ:KDMN)’s stock price was up 5.6% on Thursday . The company traded as high as $4.16 and last traded at $4.15. Approximately 136,971 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 3,960,301 shares. The stock had previously closed at $3.93.
A number of analysts recently issued reports on the stock. Jefferies Financial Group raised their price objective on shares of Kadmon from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Monday. Zacks Investment Research raised Kadmon from a “sell” rating to a “hold” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Kadmon in a research report on Friday, March 26th. UBS Group started coverage on Kadmon in a research note on Thursday, May 20th. They set a “buy” rating and a $9.00 price target for the company. Finally, Oppenheimer boosted their price objective on Kadmon from $8.00 to $9.00 and gave the company an “outperform” rating in a research note on Monday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Kadmon presently has a consensus rating of “Buy” and an average price target of $11.83.
The company’s 50 day simple moving average is $3.88. The company has a market cap of $730.87 million, a P/E ratio of -6.36 and a beta of 1.56. The company has a debt-to-equity ratio of 16.51, a current ratio of 11.00 and a quick ratio of 11.00.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Integral Health Asset Management LLC bought a new position in shares of Kadmon in the first quarter worth $1,167,000. Geode Capital Management LLC grew its position in Kadmon by 11.2% during the first quarter. Geode Capital Management LLC now owns 2,875,705 shares of the company’s stock worth $11,186,000 after buying an additional 289,592 shares in the last quarter. Gilder Gagnon Howe & Co. LLC bought a new position in Kadmon in the 1st quarter worth about $1,874,000. Principal Financial Group Inc. raised its holdings in shares of Kadmon by 52.4% in the 4th quarter. Principal Financial Group Inc. now owns 79,889 shares of the company’s stock valued at $332,000 after acquiring an additional 27,461 shares in the last quarter. Finally, Samsara BioCapital LLC bought a new stake in shares of Kadmon during the 4th quarter valued at about $685,000. Institutional investors and hedge funds own 96.86% of the company’s stock.
Kadmon Company Profile (NASDAQ:KDMN)
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer.
Featured Article: What does an inverted yield curve signify?
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.